Florida Clinical Trial Facility Owners Plead Guilty to Falsifying Asthma Drug Study Data
Key Insights
Owners of A&R Research Group (search), Ricardo Acuna (search) and Angela Baquero (search), have pleaded guilty to conspiracy to commit wire fraud for fabricating data in asthma (search) medication clinical trials.
The defendants admitted to enrolling unqualified participants and falsifying medical records including spirometry readings and echocardiogram data to secure payments from drug sponsors.
Dr. Matthew Telster (search), the clinical investigator, separately pleaded guilty to making false statements to FDA officials, admitting he lied about being present for all participant visits.
Two Florida medical research facility owners have admitted to falsifying critical data during clinical trials for asthma (search) medications, potentially compromising drug safety evaluations and patient care.
Ricardo Acuna (search), 52, and Angela Baquero (search), 49, owners of Pembroke Pines-based A&R Research Group (search), pleaded guilty Monday to conspiracy to commit wire fraud charges. According to the U.S. Justice Department, the pair deliberately manipulated clinical trial data for asthma (search) medications seeking Food and Drug Administration (search) (FDA) approval.
Details of the Fraud Scheme
The co-owners admitted to multiple fraudulent practices designed to secure payments from pharmaceutical sponsors while circumventing proper clinical protocols. Their deceptive actions included:
- Enrolling participants who did not meet study qualification criteria
- Fabricating case histories for non-existent participants
- Falsifying spirometry readings, a critical pulmonary function test for asthma assessment
- Manufacturing fraudulent echocardiogram data
- Providing falsified information to FDA investigators
"In their plea deals, Acuna and Baquero admitted to enrolling people who did not qualify into the trial and gave an FDA investigator data on people who were not participating, all for the sake of profit," according to court documents.
Clinical Investigator Also Pleads Guilty
The fraud extended beyond the facility owners. Dr. Matthew Telster (search), 70, the clinical investigator responsible for the trials, separately pleaded guilty last week to making false statements to FDA officials. The Hollywood, Florida resident admitted to lying when he claimed to be present for every participant visit during the asthma (search) medication trials.
As the designated principal investigator, Dr. Telster was responsible for performing physical examinations on study subjects and maintaining accurate records throughout the trial period. His failure to properly oversee the clinical process represents a significant breach of research protocol and medical ethics.
Potential Sentencing and Industry Impact
All three defendants face substantial legal consequences for their actions:
- Acuna and Baquero each face up to five years in federal prison when sentenced in September
- Dr. Telster also faces a maximum five-year sentence at his June hearing
This case highlights critical vulnerabilities in the clinical trial system that can potentially compromise drug safety evaluation processes. Fraudulent clinical data not only wastes pharmaceutical research resources but potentially puts patients at risk if medications are approved based on manipulated efficacy or safety profiles.
Implications for Clinical Research Integrity
This fraud case emerges amid growing concerns about clinical trial oversight and data integrity in pharmaceutical research. The FDA relies heavily on accurate clinical trial data to evaluate drug safety and efficacy before granting market approval.
When research facilities falsify data, they undermine the entire drug development process. Asthma (search) affects approximately 25 million Americans, including 5.1 million children, making reliable clinical research for respiratory medications particularly important for public health.
Regulatory Response
The case may prompt increased FDA scrutiny of clinical trial facilities, particularly smaller research organizations conducting trials for respiratory medications. Industry experts suggest this could lead to enhanced verification protocols and more frequent unannounced site inspections to ensure data integrity.
The FDA has previously emphasized the importance of data integrity in clinical research through various guidance documents, but cases like this demonstrate the continuing challenges in maintaining research standards across all trial facilities.